Metagenomi, Inc. (MGX) AI Stock Analysis

• Market Cap: $75.60M
• Dividend Yield: N/A
• Average Volume (3M): 488.08K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.97
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 236
• Sector: General
• Sector Strength: N/A
• Industry: Biotechnology
• EPS (TTM): -2.50
• Shares Outstanding: 37,423,916
• 10 Day Avg. Volume: 347,742
• 30 Day Avg. Volume: 488,076
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 1.77
• Price to Cash Flow (P/CF): -0.70
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $25.00
• Price Target Upside: 1137.62% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

Metagenomi, Inc.'s overall stock score reflects its robust revenue growth but is offset by significant profitability and cash flow challenges. Technical analysis signals a bearish sentiment with some potential for reversal. Valuation is hindered by negative earnings and absence of dividends. Recent corporate events positively impact the outlook by potentially strengthening leadership and competitive positioning.

Positive Factors

Gene Editing Advances

MGX is developing SMART nucleases small enough to fit in an AAV vector as well as adenine base editors, CRISPR-associated transposases (CASTs) and RNA-mediated integration approaches.

Hemophilia A Program

Metagenomi reported 16-month data for its Hemophilia A program in non-human primates showing enhanced durability, which is particularly important given limitations of traditional episomal gene therapy approaches.

Negative Factors

Data Variability

There is variability from subject to subject in the dataset, with the three NHP subjects experiencing greatly variable levels of FVIII expression outcome.

Metagenomi, Inc. Business Overview & Revenue Model

Company Description

At Metageno­mi, we are cre­at­ing poten­tial­ly cura­tive ther­a­peu­tics using our metage­­nomics-pow­ered genome edit­ing toolbox.We believe tools with capa­bil­i­ties that go beyond the cur­rent tech­nol­o­gy land­scape will be required in order to reach the full ther­a­peu­tic poten­tial of genome edit­ing. By har­ness­ing the pow­er of metage­nomics, the study of genomes recov­ered from uncul­ti­vat­ed organ­isms in the nat­ur­al envi­ron­ment, we are dis­cov­er­ing and devel­op­ing asuite of nov­el genome edit­ing tools with the poten­tial to make any desired ther­a­peu­tic gene edit, any­where in the human genome.

How the Company Makes Money

Metagenomi, Inc. generates revenue primarily through collaborations and partnerships with pharmaceutical and biotechnology companies. These partnerships typically involve the licensing of Metagenomi's gene-editing technology for the development of therapeutic products, allowing the company to earn milestone payments and royalties based on the success of the partners' development efforts. Additionally, Metagenomi may engage in service agreements where they provide tailored gene-editing solutions to clients, further contributing to their revenue stream. The company's income is significantly influenced by the success of its partnerships and the demand for innovative gene-editing technologies in various sectors.

Metagenomi, Inc. Financial Statement Overview

Summary

Metagenomi, Inc. exhibits strong revenue growth but faces challenges in profitability and cash flow. The balance sheet shows a solid equity base, though high liabilities relative to assets could pose future risks. Continued focus on improving operational efficiency and managing cash flow is crucial for financial stability.

Income Statement

Metagenomi, Inc. has shown considerable revenue growth, increasing from $17.2M in 2022 to $55.08M in TTM. However, the company struggles with profitability as indicated by negative EBIT and net income margins, suggesting ongoing operational challenges in achieving profitability.

Balance Sheet

The company maintains a strong equity position with a substantial stockholders' equity of $255.77M and a manageable debt-to-equity ratio of 0.18 as of TTM. However, the high total liabilities compared to total assets indicate potential leverage risks.

Cash Flow

Operating cash flow is negative, reflecting cash outflows from operations. The free cash flow has also deteriorated, pointing to potential liquidity challenges. Despite this, the company has managed to secure financing to support operations.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021
Income Statement		Total Revenue
55.08M	44.76M	17.20M	243.00K
	Gross Profit
51.30M	-49.65M	15.47M	-144.00K
	EBIT
-88.47M	-78.49M	-44.64M	-23.95M
	EBITDA
-79.70M	-56.02M	-39.19M	-20.75M
	Net Income Common Stockholders
-73.95M	-68.25M	-43.59M	-21.44M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
362.13M	271.18M	362.13M	108.15M
	Total Assets
414.49M	364.84M	414.49M	141.99M
	Total Debt
18.57M	48.23M	18.57M	48.93M
	Net Debt
-165.87M	-92.37M	-165.87M	9.63M
	Total Liabilities
488.91M	500.43M	488.91M	174.54M
	Stockholders Equity
-74.43M	-135.58M	-74.43M	-32.54M
Cash Flow		Free Cash Flow
-107.91M	-101.22M	15.75M	21.35M
	Operating Cash Flow
-103.39M	-91.41M	29.72M	24.26M
	Investing Cash Flow
-56.07M	45.73M	-122.20M	-74.32M
	Financing Cash Flow
82.68M	1.01M	239.59M	39.92M

Metagenomi, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MGX, the sentiment is Negative. The current price of 2.02 is below the 20-day moving average (MA) of 2.19, below the 50-day MA of 2.64, and below the 200-day MA of 3.17, indicating a bearish trend. The MACD of -0.18 indicates Negative momentum. The RSI at 40.80 is Neutral, neither overbought nor oversold. The STOCH value of 59.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MGX.

Metagenomi, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$4.56B	-16.15	-11.85%	4.78%	31.69%	-53.77%
CRSP	48 Neutral	$3.72B	―	-19.20%	―	-89.95%	-123.71%
BEAM	47 Neutral	$2.21B	―	-43.94%	―	-83.18%	-144.95%
MGX	47 Neutral	$75.60M	―	-30.34%	―	―	―
SGMO	42 Neutral	$206.96M	―	-156.42%	―	-74.04%	48.16%
EDIT	42 Neutral	$129.44M	―	-98.10%	―	-58.64%	-40.05%
NTLA	39 Underperform	$962.71M	―	-54.00%	―	59.55%	3.09%

Metagenomi, Inc. Corporate Events

Metagenomi Expands Leadership and Showcases Innovations

On January 13, 2025, Metagenomi, Inc. announced the expansion of its board of directors by appointing Eric Bjerkholt as a new director, effective January 27, 2025. This move is part of Metagenomi’s strategic efforts to strengthen its leadership team as it continues to advance its genetic medicine programs. Bjerkholt’s extensive experience in the biopharmaceutical sector is expected to significantly contribute to the company’s growth and operational strategies. Alongside, Metagenomi updated its presentation for the 43rd Annual J.P. Morgan Healthcare Conference, showcasing its developments in gene editing technologies, which may enhance its competitive standing in the biotechnology market.